ADC Therapeutics stock plunges 53% after-hours as investors focus on safety concerns in a phase III DLBCL study of Zynlonta, ...

Higher rates of adverse events offset the positive survival results in an area of great unmet need. For decades, the standard ...

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs ...

By Christy Santhosh May 30 (Reuters) - Incyte's Monjuvi as part of a multi-drug regimen that includes a chemotherapy standard of care for an aggressive form of non-Hodgkin lymphoma reduced the risk of ...

ADC Therapeutics SA ADCT stock is trading lower on Thursday after the company indicated that LOTIS-5 showed elevated serious and Grade 5 adverse events, and it will discuss the benefit-risk profile ...

This type of cancer begins in the body’s white blood cells, called lymphocytes, which are part of the immune system. 3 NHL develops when a lymphocyte undergoes a malignant (cancerous) change and then ...

Add-on tafasitamab and lenalidomide did not negatively impact chemotherapy backbone ...

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns ...

Researchers have identified four genetic subtypes of diffuse large B-cell lymphoma (DLBCL) that may explain why some patients respond to treatment and others don't and provide a path toward precision ...